Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X.

J Immunol. 2011 Jan 15;186(2):1022-31. doi: 10.4049/jimmunol.0902147. Epub 2010 Dec 17.

2.
3.

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.

Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.

Vaccine. 2011 Jul 26;29(33):5481-7. doi: 10.1016/j.vaccine.2011.05.062. Epub 2011 Jun 12.

PMID:
21664216
4.

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.

Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ.

Vaccine. 2008 Jan 10;26(2):201-14. Epub 2007 Nov 20.

PMID:
18063235
5.

Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Lee YN, Lee YT, Kim MC, Hwang HS, Lee JS, Kim KH, Kang SM.

Immunology. 2014 Oct;143(2):300-9. doi: 10.1111/imm.12310.

6.

Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine.

Adler-Moore J, Munoz M, Kim H, Romero J, Tumpey T, Zeng H, Petro C, Ernst W, Kosina S, Jimenez G, Fujii G.

Vaccine. 2011 Jun 15;29(27):4460-8. doi: 10.1016/j.vaccine.2011.04.040. Epub 2011 May 3.

PMID:
21545821
7.

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londoño-Arcila P, Fiers W, Saelens X.

Vaccine. 2008 Dec 2;26(51):6503-7. doi: 10.1016/j.vaccine.2008.09.038.

PMID:
18835315
8.

An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.

Ma JH, Yang FR, Yu H, Zhou YJ, Li GX, Huang M, Wen F, Tong G.

Virol J. 2013 Jul 9;10:227. doi: 10.1186/1743-422X-10-227.

9.

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.

Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10.

PMID:
18243429
10.

In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.

Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH.

Virology. 2012 Aug 15;430(1):63-72. doi: 10.1016/j.virol.2012.04.015. Epub 2012 May 16.

11.

Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.

Kim EH, Park HJ, Han GY, Song MK, Pereboev A, Hong JS, Chang J, Byun YH, Seong BL, Nguyen HH.

J Virol. 2014 Sep 1;88(17):9693-703. doi: 10.1128/JVI.00823-14. Epub 2014 Jun 11.

12.

Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Van den Hoecke S, Ehrhardt K, Kolpe A, El Bakkouri K, Deng L, Grootaert H, Schoonooghe S, Smet A, Bentahir M, Roose K, Schotsaert M, Schepens B, Callewaert N, Nimmerjahn F, Staeheli P, Hengel H, Saelens X.

J Virol. 2017 Mar 13;91(7). pii: e02500-16. doi: 10.1128/JVI.02500-16. Print 2017 Apr 1.

13.
14.

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

Wu F, Yuan XY, Huang WS, Chen YH.

Vaccine. 2009 Oct 9;27(43):6095-101. doi: 10.1016/j.vaccine.2008.11.037. Epub 2008 Dec 3.

PMID:
19056447
15.

An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.

Zhao G, Sun S, Du L, Xiao W, Ru Z, Kou Z, Guo Y, Yu H, Jiang S, Lone Y, Zheng BJ, Zhou Y.

Virol J. 2010 Jul 12;7:151. doi: 10.1186/1743-422X-7-151.

16.

In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine.

Jazi MH, Dabaghian M, Tebianian M, Gharagozlou MJ, Ebrahimi SM.

Virus Res. 2012 Aug;167(2):219-25. doi: 10.1016/j.virusres.2012.05.002. Epub 2012 May 16.

PMID:
22609252
17.

Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T.

PLoS One. 2012;7(9):e45765. doi: 10.1371/journal.pone.0045765. Epub 2012 Sep 24.

18.

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, Maudrich M, Pumpens P, Saudan P, Bachmann MF.

Eur J Immunol. 2012 Apr;42(4):863-9. doi: 10.1002/eji.201041225.

19.

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, Zheng BJ, Zhou Y.

Virol J. 2010 Jan 18;7:9. doi: 10.1186/1743-422X-7-9.

20.

Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein.

Andersson AM, Håkansson KO, Jensen BA, Christensen D, Andersen P, Thomsen AR, Christensen JP.

PLoS One. 2012;7(10):e46395. doi: 10.1371/journal.pone.0046395. Epub 2012 Oct 1.

Supplemental Content

Support Center